The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer.
 
Neelima Vidula
Consulting or Advisory Role - Abbvie
Research Funding - DAEHWA Pharmaceutical (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst)
Travel, Accommodations, Expenses - Pfizer (Inst)
 
Erica Blouch
No Relationships to Disclose
 
Nora K. Horick
Employment - Northwest Biotherapeutics (I)
Stock and Other Ownership Interests - Northwest Biotherapeutics (I)
Patents, Royalties, Other Intellectual Property - An immediate family member holds patents, has patents pending, and receives royalties from a technology relating to health or medicine. (I)
 
Erin Basile
Stock and Other Ownership Interests - Moderna Therapeutics (I); Pfizer (I)
 
Senthil Damodaran
Honoraria - Novartis
Research Funding - EMD Serono (Inst); Guardant Health (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Phillips Gilmore Oncology Communications
 
Minetta C. Liu
Research Funding - Eisai (Inst); Genomic Health (Inst); GRAIL (Inst); Menarini Silicon Biosystems (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Genomic Health; GRAIL; Ionis Pharmaceuticals (Inst); Menarini Silicon Biosystems; Merck; Pfizer
 
Ami N. Shah
No Relationships to Disclose
 
Alvaro Moreno-Aspitia
Stock and Other Ownership Interests - Merrimack
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from the development of a xenograft model. Royalties were assigned to go to my institution and not personally
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology
Consulting or Advisory Role - Samsung
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; Pfizer
 
Leif Ellisen
No Relationships to Disclose
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)